Family medicine clinicians must recognize that GLP-1 receptor agonists and tirzepatide produce lean mass loss disproportionate to fat mass loss, which can compromise functional capacity and metabolic rate in patients who appear to be achieving appropriate weight reduction on the scale. This finding necessitates concurrent resistance training prescription and dietary protein optimization as standard components of GLP-1 therapy management rather than optional adjuncts. Patients on these agents require baseline and periodic assessment of functional metrics beyond weight to identify clinically significant sarcopenia risk, particularly in older adults where lean mass preservation directly impacts independence and reduces fracture risk.

A recent study examined body composition changes in patients receiving GLP-1 receptor agonists and GLP-1/GIP receptor agonists for weight management. The investigation included 35 participants distributed across liraglutide (n=22), semaglutide (n=10), and tirzepatide (n=3) treatment groups. The primary objective was to quantify the proportion of weight loss attributable to lean mass versus fat mass, addressing a gap in the clinical literature regarding the metabolic effects of these increasingly prescribed agents.

The findings demonstrate that GLP-1 and GLP-1/GIP agonists produce greater lean mass loss during weight reduction than previously expected based on clinical observations. This distinction carries important implications for prescribing practice, as preservation of skeletal muscle is a critical consideration in weight management and long-term metabolic health. The degree of lean mass loss varies with the pharmacologic agent used, with semaglutide and liraglutide showing measurable differences in body composition changes compared to tirzepatide, though the small tirzepatide cohort limits definitive comparison between dual agonists and GLP-1 selective agonists.

These findings suggest that clinicians should counsel patients on the importance of resistance training and adequate protein intake during GLP-1 or GLP-1/GIP agonist therapy to mitigate unintended lean mass depletion. The data support a more nuanced approach to GLP-1 prescription that incorporates structured exercise recommendations and nutritional optimization as integral components of treatment protocols rather than adjunctive considerations.

Clinical Takeaway:

GLP-1 receptor agonists and tirzepatide produce meaningful reductions in lean muscle mass alongside fat loss, a pattern not always proportional to overall weight reduction. This lean mass loss occurs across all three major drug classes (liraglutide, semaglutide, and tirzepatide) and warrants monitoring in clinical practice. Patients should be counseled to maintain adequate protein intake and engage in resistance exercise during weight loss to help preserve muscle function and metabolic health. Consider asking patients about their exercise habits and protein consumption at baseline and during follow-up visits, as these modifiable factors can significantly influence body composition outcomes alongside pharmacotherapy.

“This study highlights a real clinical concern that we need to address head-on with our patients: GLP-1 receptor agonists and tirzepatide do appear to preferentially mobilize lean mass alongside fat mass, particularly in the early phases of treatment. The mechanism likely involves both the appetite suppression and the metabolic shifting that occurs with these agents, which is why I’ve shifted my practice toward more aggressive protein supplementation and resistance training counseling from day one of therapy. When I’m initiating these medications, I now explicitly tell patients that hitting their protein targets (roughly 1.6 to 2.2 grams per kilogram of body weight) and maintaining or increasing strength training are not optional add-ons but rather essential components of the treatment plan itself. This reframing has markedly improved patient adherence to exercise and nutritional strategies that would otherwise get deprioritized once they experience rapid initial weight loss.”

? Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

Have thoughts on this? Share it: